Dr. Silverberg discusses how to safely counsel patients when deciding between topical versus oral JAK inhibitors for the treatment of atopic dermatitis.
Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients (2 to 11 years) with atopic dermatitis.
...